Modern Study Review (AI-Generated)
High-Yield Summary
Giant Cell Tumor (GCT) of bone is a locally aggressive, benign neoplasm characterized by multinucleated giant cells and stromal mononuclear cells. It predominantly affects young adults in the third decade of life, with a slight female predominance. GCTs most commonly arise in the epiphyseal region of long bones, causing pain, swelling, and potential joint dysfunction. Early diagnosis and appropriate management are critical to prevent local recurrence and preserve function.
Key Diagnostic Findings
Anatomy
- Originates from stromal cells of the bone marrow within the epiphysis of long bones.
- Most common sites: distal femur, proximal tibia, distal radius, and sacrum.
Clinical Presentation
- Age: Typically 20-40 years old, peak incidence in the 3rd decade.
- Gender: Slight female predominance.
- Symptoms: Localized pain, swelling, decreased joint motion, and sometimes pathological fracture.
Imaging
- X-ray: Eccentric, lytic, expansile lesion in the epiphysis extending to metaphysis without sclerotic margins.
- MRI: Defines soft tissue extension and cystic/hemorrhagic components.
- CT: Useful for cortical breach and surgical planning.
Classification Systems
| Classification | Description | Clinical Use |
|---|---|---|
| Campanacci Grading | Grade 1: latent, well-marginated; Grade 2: active, well-defined but no soft tissue extension; Grade 3: aggressive with soft tissue extension | Guides surgical planning and prognosis |
Current Gold Standard Treatment
Non-operative
- Reserved for small, asymptomatic lesions or patients unfit for surgery.
- Denosumab: A RANKL inhibitor used as neoadjuvant therapy to reduce tumor size and facilitate surgery or as palliative treatment in unresectable cases.
Operative
- Extended curettage with adjuvants (e.g., phenol, liquid nitrogen, PMMA cement) is the mainstay to reduce recurrence.
- En bloc resection for aggressive or recurrent tumors with soft tissue extension.
- Reconstruction depends on defect size and location.
Modern Complications & Outcomes
Complications
| Complication | Description |
|---|---|
| Local recurrence | Occurs in up to 20-30% after curettage; reduced with adjuvants and cementation. |
| Pathological fracture | Common due to bone destruction. |
| Malignant transformation | Rare, usually after radiation therapy. |
| Joint stiffness and dysfunction | Due to tumor location and surgical intervention. |
Outcomes
- Functional outcomes are generally good with extended curettage and adjuvants.
- Denosumab improves surgical outcomes but requires monitoring for rebound tumor growth after cessation.
- Long-term surveillance is essential due to risk of recurrence.
Classic Clinical Notes
Giant Cell Tumor
- derives from cellular elements of bone marrow
- females > males; 3rd decade but rare
Last Updated on January 25, 2026 by orthonet
Leave a Reply
Want to join the discussion?Feel free to contribute!